These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24762166)

  • 1. Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study).
    Tazarourte K; Riou B; Tremey B; Samama CM; Vicaut E; Vigué B;
    Crit Care; 2014 Apr; 18(2):R81. PubMed ID: 24762166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice.
    Desmettre T; Dehours E; Samama CM; Jhundoo S; Pujeau F; Guillaudin C; Hecquart C; Clerson P; Crave JC; Jaussaud R
    Crit Care; 2012 Oct; 16(5):R185. PubMed ID: 23036234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists.
    Müller M; Eastline J; Nagler M; Exadaktylos AK; Sauter TC
    Scand J Trauma Resusc Emerg Med; 2019 Apr; 27(1):48. PubMed ID: 31014373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate.
    Majeed A; Meijer K; Larrazabal R; Arnberg F; Luijckx GJ; Roberts RS; Schulman S
    Thromb Haemost; 2014 Feb; 111(2):233-9. PubMed ID: 24154891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
    Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
    Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial.
    Steiner T; Poli S; Griebe M; Hüsing J; Hajda J; Freiberger A; Bendszus M; Bösel J; Christensen H; Dohmen C; Hennerici M; Kollmer J; Stetefeld H; Wartenberg KE; Weimar C; Hacke W; Veltkamp R
    Lancet Neurol; 2016 May; 15(6):566-73. PubMed ID: 27302126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis.
    Abdoellakhan RA; Miah IP; Khorsand N; Meijer K; Jellema K
    Neurocrit Care; 2017 Feb; 26(1):64-69. PubMed ID: 27052728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prothrombin Complex Concentrate for Vitamin K Antagonist-Associated Intracranial Hemorrhage　- Global Evidence and the Japanese Perspective.
    Yasaka M; Brainsky A; Toyoda K
    Circ J; 2017 Oct; 81(11):1564-1573. PubMed ID: 28724836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase 3b study.
    Kushimoto S; Fukuoka T; Kimura A; Toyoda K; Brainsky A; Harman A; Chung T; Yasaka M
    Int J Hematol; 2017 Dec; 106(6):777-786. PubMed ID: 28815410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis.
    Pan R; Cheng J; Lai K; Huang Q; Wu H; Tang Y
    Neurol Sci; 2019 Apr; 40(4):813-827. PubMed ID: 30689075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergency reversal of anticoagulation: the real use of prothrombin complex concentrates: a prospective multicenter two year French study from 2006 to 2008.
    Desmettre T; Dubart AE; Capellier G; Fanara B; Puyraveau M; Kepka S; Coquart J; Sheppard F; Tazarourte K
    Thromb Res; 2012 Sep; 130(3):e178-83. PubMed ID: 22726885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
    Bitonti MT; Rumbarger RL; Absher RK; Curran LM
    J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real world usage of PCC to "rapidly" correct warfarin induced coagulopathy.
    Toth P; van Veen JJ; Robinson K; Maclean RM; Hampton KK; Laidlaw S; Makris M
    Blood Transfus; 2013 Oct; 11(4):500-5. PubMed ID: 23114527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy.
    Khorsand N; Kooistra HA; van Hest RM; Veeger NJ; Meijer K
    Thromb Res; 2015 Jan; 135(1):9-19. PubMed ID: 25480313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis.
    Brekelmans MPA; Ginkel KV; Daams JG; Hutten BA; Middeldorp S; Coppens M
    J Thromb Thrombolysis; 2017 Jul; 44(1):118-129. PubMed ID: 28540468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials.
    Milling TJ; Refaai MA; Sarode R; Lewis B; Mangione A; Durn BL; Harman A; Lee ML; Goldstein JN
    Acad Emerg Med; 2016 Apr; 23(4):466-75. PubMed ID: 26822172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prothrombin complex concentrate for vitamin K antagonist reversal in traumatic intracranial hemorrhage.
    Beynon C; Nofal M; Rizos T; Laible M; Sakowitz OW; Unterberg AW
    J Clin Neurosci; 2020 Sep; 79():197-202. PubMed ID: 33070895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal: Does One Dose Fit All?
    Schwebach AA; Waybright RA; Johnson TJ
    Pharmacotherapy; 2019 May; 39(5):599-608. PubMed ID: 30892733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergent reversal of vitamin K antagonists: addressing all the factors.
    Martin DT; Barton CA; Dodgion C; Schreiber M
    Am J Surg; 2016 May; 211(5):919-25. PubMed ID: 27046797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four-factor prothrombin complex concentrate versus plasma for urgent vitamin K antagonist reversal: new evidence.
    Sarode R
    Clin Lab Med; 2014 Sep; 34(3):613-21. PubMed ID: 25168946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.